Please find enclosed press release titled "Fredun Pharmaceuticals Reports 61% YoY Growth in EBITDA to 39.33 Cr in H1 FY26" issued by Fredun Pharmaceutcals Limited.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals reported strong H1 FY26 results, with total income rising 42% YoY to ₹265.15 Cr and EBITDA growing nearly 61% YoY to ₹39.33 Cr, pushing EBITDA margin up 171 basis points to 14.83%. Net profit nearly doubled, jumping 96% YoY to ₹16.50 Cr, while EPS rose to ₹34.94 from ₹17.80. In Q2 alone, revenue grew 35% YoY to ₹145.29 Cr and net profit more than doubled to ₹9.73 Cr. The company also announced a 7% final dividend, a preferential issue of equity shares and warrants at ₹1,250 each, two acquisitions in pet-tech (Wagr.ai and One Pet Stop), and the launch of Snacky Jain, billed as India's first Jain-compliant pet food. Management highlighted expansion of its Palghar manufacturing facility and continued momentum in domestic formulations and exports.
Strong top-line and bottom-line growth, expanding margins, and a 7% dividend are positive signals for shareholders, though the preferential issue at ₹1,250/share could lead to some dilution. The aggressive push into pet healthcare through acquisitions and new products opens a new growth vertical beyond core pharma.